BMS cuts 479 jobs; GlaxoSmithKline wins award; new biosimilars plant planned in China;

> Bristol-Myers Squibb ($BMY) will cut 479 positions from its Plainsboro, NJ, support facility. Story

> Compliance consultants Pharmatech Associates, has won a deal with Innovent Biologics for facility design and compliance support for a biosimilars manufacturing operation in Suzhou, China. Item

> India's Pharmaceuticals Export Promotion Council (Pharmexcil) plans to work with other pharmaceutical associations to open warehouses in Africa and Latin America to help small drug manufacturers expand. Story

> GlaxoSmithKline ($GSK) has won the top prize at the IChemE 2012 Awards for the changes it made in its tablet manufacturing process. Item

> Wacker Biotech has partnered with XL-protein to offer what it calls a low-cost PEGytlation alternative to its biopharmaceutical manufacturing services. Item

And Finally... Continuing its effort to keep online companies from making claims that their products can treat or cure medical conditions, the FDA has sent a warning letter to Gary Powers, CEO of Ortho Molecular Products in Woodstock, IL, saying that some of its products, such as Candicid Forte, make claims that classify them as drugs. Warning letter

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.